Kyntra Bio
KYNB
162 hedge funds and large institutions have $935M invested in Kyntra Bio in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 47 increasing their positions, 58 reducing their positions, and 28 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
42% more capital invested
Capital invested by funds: $657M → $935M (+$278M)
3% more call options, than puts
Call options by funds: $4.89M | Put options by funds: $4.77M
0.09% more ownership
Funds ownership: 2.77% → 2.86% (+0.09%)
4% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 28
1% less funds holding
Funds holding: 164 → 162 (-2)
19% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.6M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$19.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$13.1M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.75M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$25M |
| 2 |
JP Morgan Chase
New York
|
-$14.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.65M |
| 4 |
Millennium Management
New York
|
-$7.34M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.56M |
KYNB Hedge Fund Activity: Q4 2021 in Review
162 of the 6,439 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2021, worth a combined $935M — up 42% from $657M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of KYNB and 27 opened new positions — a net loss of 1 holder — while 58 trimmed existing stakes and 47 added.
The largest buyer was Point72 Asset Management, adding an estimated $32.6M. The largest seller was State Street, cutting an estimated $25M.
- 162 institutional investors held Kyntra Bio (KYNB) as of Q4 2021, down from 164 in Q3 2021.
- Funds reported $935M of Kyntra Bio stock for Q4 2021, up 42% quarter-over-quarter.
- 27 funds opened new Kyntra Bio positions in Q4 2021 and 28 closed out, a net change of -1 holder.
- The largest Kyntra Bio buyer in Q4 2021 was Point72 Asset Management, an estimated $32.6M added.
- The largest Kyntra Bio seller in Q4 2021 was State Street, an estimated $25M sold.
Based on aggregated 13F filings for Q4 2021.